Neurocrine Biosciences strengthens INGREZZA case with functional improvement data
Mild TD can still disrupt work and independence. Neurocrine’s INGREZZA data raises pressure to rethink when treatment begins.
Merz Therapeutics tests the long game in neurorehabilitation with XEOMIN data
Spasticity care is not one injection cycle. Merz Therapeutics is pushing XEOMIN data toward durability, dosing flexibility and patient goals.
Could Praxis Precision Medicines’ Phase 3 ulixacaltamide data redefine the treatment pathway in essential tremor?
Praxis Precision Medicines’ positive Phase 3 ulixacaltamide data could reshape essential tremor treatment. Discover what this means for neurology and investors.